Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the potential treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs for frontotemporal dementia and Alzheimer’s disease, as well as for immuno-oncology programs. Alector is headquartered in South San Francisco, California. Additional information can be found at www.alector.com.